Affinity purified from pooled serum. Learn more.

MerTK Tyr749/753/754 Antibody

We are the original manufacturer of our MerTK Tyr749/753/754 rabbit polyclonal phosphospecific antibody, which is affinity purified from pooled serum. Optimized in WB.

Catalog #: p186-749 Categories: , Datasheet:

$119.00$380.00

  • SizePrice
Clear
Pooled Serum
Formulation:
Affinity Purified from Pooled Serum
Species Tested:
Human, Mouse, Rat
Expected Reactivity:
Avian, Bovine, Canine, Guinea Pig, Non-human primate
Applications:
WB 1:1000 Don't see your application?
Host Species:
Rabbit Polyclonal
Gene Name:
MERTK
Molecular Weight:
160 kD
Cite This Antibody:
PhosphoSolutions Cat# p186-749: RRID:AB_2744537
Antigen/Purification: ExpandCollapse

Phosphopeptide corresponding to amino acid residues surrounding the phospho-Tyr749/753/754 of human MerTK.

Prepared from pooled rabbit serum by affinity purification via sequential chromatography on phospho and non-phosphopeptide affinity columns.

 

Biological Significance: ExpandCollapse

Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).

Synonyms: ExpandCollapse

• c MER antibody
• c mer proto oncogene tyrosine kinase antibody
• c-mer antibody
• cMER antibody
• cmer protooncogene tyrosine kinase antibody
• Eyk antibody
• MER antibody
• MER receptor tyrosine kinase antibody
• MERK antibody
• MERPEN antibody
• Mertk antibody
• MERTK c-mer proto-oncogene tyrosine kinase antibody
• MERTK_HUMAN antibody
• MGC133349 antibody
• nmf12 antibody
• Nyk antibody
• Proto oncogene tyrosine protein kinase MER antibody
• Proto oncogene tyrosine protein kinase MER precursor antibody
• Proto-oncogene c-Mer antibody
• Receptor tyrosine kinase MerTK antibody
• RP38 antibody
• STK kinase antibody
• Tyrosine-protein kinase Mer antibody

Storage

100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. Adequate amount of material to conduct 10-mini Western blots.

Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.

Product Specific Protocols

Western Blotting

Click here to view our protocols page for Western blotting and lysate preparation.

Product Specific References for Applications and Species

Western Blot: Human | Mouse


Western Blot: Human
PMID Dilution Publication
31497954 not listed Da, C., et al. 2019 Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society, 141(39):15700-15709.
30482852 not listed Sinik, L., et al. 2019 . Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular Cancer Therapeutics, 18(2), pp.278-288.
303471555 not listed Zhao, J., et al. 2018 Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
30194074 not listed Yan, D., et al. 2018 MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type EGFR Family Members. Clinical Cancer Research, 24(24), pp.6523-6535.
30093568 not listed McDaniel, N.K., et al. 2018 MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics, 17(11), pp.2297-2308.
29045015 not listed Branchford, B.R., et al. 2018 The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
27783662 not listed Sufit, A., et al. 2016 MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PLoS One, 11(10):e0165107.
27649555 not listed DeRyckere, D., et al. 2017 UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 23(6):1481-1492.
27158668 not listed Minson, K.A., et al. 2016 The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight, 1(3):e85630.
26162689 not listed Cummings, C.T., et al. 2015 Small molecule inhibition of MERTK is efficacious in non-smal cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics, 14(9):2014-2022.
25762638 not listed Lee-Sherick, A.B., et al. 2015 Efficacy of a Mer and lt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 6(9):6722-36.
25372020 not listed Cummings, C.T., et al. 2015 Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget, 5(21):10434-45.
24219778 not listed Zhang, W., et al. 2013 Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762 not listed Zhang, W., et al. 2013 Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.
23997116 not listed Christoph, S., et al. 2013 UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics, 12(11):2367-77.
23693152 not listed Liu, J., et al. 2013 UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry, 65:83-93.
23585477 not listed Schlegel, J., et al. 2013 MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 123(5):2257-67.
23474756 not listed Lee-Sherick, A.B., et al. 2013 Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene, 32(46):5359-68.
23353780 not listed Brandao, L.N., et al. 2013 Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal, 3:e101.
22890323 not listed Linger, R., et al. 2013 Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer. Oncogene, 32(29):3420-3431.


Western Blot: Mouse
PMID Dilution Publication
303471555 not listed Zhao, J., et al. 2018 Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry, 61(22), pp.10242-10254.
29045015 not listed Branchford,B.R., et al. 2017 The small‐molecule MERTK inhibitor UNC 2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis, 16(2), pp.352-363.
25068800 not listed Zhang, W, et al. 2014 UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry, 57(16), pp.7031-7041.
24219778 not listed Zhang, W, et al. 2013 Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry, 56(23), pp.9693-9700.
24195762 not listed Zhang, W, et al. 2013 Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry, 56(23), pp.9683-9692.

  • 5 – Excellent (publishable, performed ideally)
  • 4 – Good (publishable, would use again)
  • 3 – Average (publishable, might use again)
  • 2 – Poor (unpublishable, signal inconclusive)
  • 1 – No signal (unpublishable)
Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

You may also like…